Dermatitis News

Recent articles on hidradenitis suppurativa and atopic dermatitis have garnered the most pageviews so far this month at Healio Dermatology.

Brodalumab was associated with skin clearance in the treatment of moderate to severe plaque psoriasis across various subgroups defined by race or ethnicity, according to a study.

Long-term treatment adherence to secukinumab among patients with psoriasis appears to be favorable, with 24% of patients discontinuing treatment over the follow-up period of one study.

Patients with multiple sclerosis are more likely to have prevalent or incident psoriasis, but the pathway that leads to both psoriasis and MS remains unclear, according to a literature review.

Researchers from Stanford University discovered new regional dermatoses mainly on the face in a cohort of adults with atopic dermatitis taking dupilumab, in the most popular Healio Dermatology research news from the past week.

The endocannabinoid system is functional in the skin, responsible for many aspects of skin homeostasis, and offers potential targets for the management of inflammatory skin conditions, according to a literature review.

Researchers explored the skin-related conditions associated with electronic cigarette use in the most popular Healio Dermatology article last month.

In a cohort of adults with atopic dermatitis who were taking dupilumab, nearly a quarter of patients developed new regional dermatoses appearing mostly on the face.

Novartis, along with biopharmaceutical companies MorphoSys and Galapagos, announced the initiation of GECKO, a phase 2 study exploring a subcutaneous formulation of MOR106 combined with topical corticosteroids in patients with moderate to severe atopic dermatitis.

Patients with a higher BMI have a greater risk for psoriasis, according to researchers who support healthy lifestyle initiatives for weight management in psoriasis prevention and treatment.